CO5550467A2 - Conjugados inmunogenicos de acido hialuronico de bajo peso molecular con toxinas polipeptidas - Google Patents

Conjugados inmunogenicos de acido hialuronico de bajo peso molecular con toxinas polipeptidas

Info

Publication number
CO5550467A2
CO5550467A2 CO03099742A CO03099742A CO5550467A2 CO 5550467 A2 CO5550467 A2 CO 5550467A2 CO 03099742 A CO03099742 A CO 03099742A CO 03099742 A CO03099742 A CO 03099742A CO 5550467 A2 CO5550467 A2 CO 5550467A2
Authority
CO
Colombia
Prior art keywords
molecular weight
low molecular
hyaluronic acid
immunogenic conjugates
acid
Prior art date
Application number
CO03099742A
Other languages
English (en)
Inventor
Francis Michon
Samuel Moore
Laude-Sharp Maryline
Milan Blake
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO5550467A2 publication Critical patent/CO5550467A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

1.- Una molécula de conjugado inmunogénico que comprende ácido hialurónico ligado covalentemente a un portador de polipéptido inmunologicamente aceptable.2.- El conjugado inmunogénico de acuerdo con la reivindicación 1, en donde mayor acerca de 50% de las moléculas de ácido hialurónico poseen un terminal no reductor de ácido glucurónico y/o un residuo de ácido glucurónico no saturado.3.- El conjugado inmunogénico de acuerdo con la reivindicación 2, en donde el ácido hialurónico es un ácido hialurónico de bajo peso molecular con un paso molecular de alrededor de 400 Kd o menos y un peso molecular de alrededor de 600 daltons o más.
CO03099742A 2001-05-11 2003-11-11 Conjugados inmunogenicos de acido hialuronico de bajo peso molecular con toxinas polipeptidas CO5550467A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci

Publications (1)

Publication Number Publication Date
CO5550467A2 true CO5550467A2 (es) 2005-08-31

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
CO03099742A CO5550467A2 (es) 2001-05-11 2003-11-11 Conjugados inmunogenicos de acido hialuronico de bajo peso molecular con toxinas polipeptidas

Country Status (15)

Country Link
US (1) US20020192205A1 (es)
EP (1) EP1385554A2 (es)
JP (1) JP2005508854A (es)
KR (1) KR20030096369A (es)
CN (1) CN1525869A (es)
AR (1) AR034331A1 (es)
BR (1) BR0209562A (es)
CA (1) CA2446555A1 (es)
CO (1) CO5550467A2 (es)
EC (1) ECSP034888A (es)
HU (1) HUP0400840A3 (es)
MX (1) MXPA03010283A (es)
PL (1) PL366692A1 (es)
SK (1) SK15122003A3 (es)
WO (1) WO2002092131A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS
AU2009309416B2 (en) * 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
WO2013119061A1 (ko) * 2012-02-07 2013-08-15 포항공과대학교 산학협력단 경피 전달용 히알루론산-단백질 컨쥬게이트의 제조 방법 및 이에 따라 제조된 경피 전달용 히알루론산-단백질 컨쥬게이트
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯（天津）生物科技有限公司 一种透明质酸固相包被方法
AR111249A1 (es) 2017-03-22 2019-06-19 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
NZ502437A (en) * 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
WO1999062546A1 (en) * 1998-06-01 1999-12-09 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
US20020192205A1 (en) 2002-12-19
WO2002092131A2 (en) 2002-11-21
CA2446555A1 (en) 2002-11-21
PL366692A1 (en) 2005-02-07
KR20030096369A (ko) 2003-12-24
ECSP034888A (es) 2004-05-28
HUP0400840A2 (hu) 2004-07-28
SK15122003A3 (sk) 2004-10-05
JP2005508854A (ja) 2005-04-07
HUP0400840A3 (en) 2004-10-28
CN1525869A (zh) 2004-09-01
EP1385554A2 (en) 2004-02-04
BR0209562A (pt) 2004-03-30
WO2002092131A3 (en) 2003-03-20
AR034331A1 (es) 2004-02-18
MXPA03010283A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
CO5550467A2 (es) Conjugados inmunogenicos de acido hialuronico de bajo peso molecular con toxinas polipeptidas
ATE375387T1 (de) Modifiziertes polypeptid
EA200001111A1 (ru) КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
Duance et al. The location of three collagen types in skeletal muscle
KR910016770A (ko) 글리코사미노글리칸-변형된 단백질
BRPI0114994B8 (pt) composição de vacina
IT1248557B (it) Miscele di polisaccaridi di bassi pesi molecolari, procedimento di preparazione e impiego.
TR199701547T1 (xx) Polisakarit antijen protein e�leni�i i�eren a��.
LU90457I2 (fr) Refacto
TR200001956A2 (tr) Eritropoietin türevleri.
AR008378A1 (es) Conjudados de interferon
KR890004730A (ko) G_7rh에 대한 면역반응을 유발시키고 포유동물을 면역 불임시키기 위한 제제 및 방법
ES2460926T3 (es) Redes de proteína heterogéneas reticuladas con enlaces que contienen silicona, y procedimientos de producción de las mismas
PT1148866E (pt) Poliamidas de terminacao de amida (atpa) e utilizacao das mesmas
DE69627149T2 (de) Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe
FR2622587B1 (fr) Peptide lysyl-arginyl-aspartyl-serine et ses applications en tant que medicament, notamment antithrombotique
DE69224988D1 (de) Aminosäurederivat und bromacetyl-modifizierte peptide
KR930010177A (ko) 하이브리드 형질전환 성장인자
ATE276274T1 (de) Konjugate von alpha-msh mit einer fettsäure, verfahren zu ihrer herstellung und ihre verwendung als medikament
ES2085856T3 (es) Ester derivado de un siloxano con grupos alcoholes; composiciones cosmeticas que contienen estos derivados.
DK563585A (da) Immunotoksiner med forlaenget virkning indeholdende en glycopeptidbestanddel, som inaktiverer ribosomer, og som er modificeret i sine polysaccharidenheder, og fremgangsmaade til fremstilling af immunotoksinerne
AU1035797A (en) Process for the preparation of organic disulphides and polysulphides
PE27791A1 (es) Oligomeros de ester de sulfobenzoil de terminal tapado para soltar la suciedad en composiciones detergentes granuladas
KR830005114A (ko) Lrf 길항 물질 제조방법
KR930700549A (ko) 신규한 거핵구계 콜로니 자극인자와 그 제조방법

Legal Events

Date Code Title Description
FC Application refused